Literature DB >> 33457372

Hard-To-Treat Idiopathic Refractory Autoimmune Haemolytic Anaemia with Reticulocytopenia.

Marcelo Aveiro1, Gisela Ferreira2, Carla Matias1, Ana Oliveira1, Tatiana Rodrigues1.   

Abstract

Autoimmune haemolytic anaemia (AIHA) is an uncommon condition characterized by increased destruction of erythrocytes associated with reticulocytosis in the great majority of cases. We present the case of a 68-year-old woman with jaundice and malaise. Investigation revealed AIHA with reticulocytopenia. The patient failed to respond to prednisolone or to rituximab. Azathioprine and epoetin beta were subsequently started, the prednisolone dose was increased, and the patient began to respond after 1 month. In AIHA, reticulocytopenia is a very rare presentation and a sign of great severity and poor outcome. The scarcity of therapeutic options in refractory cases poses a major challenge for physicians. LEARNING POINTS: Autoimmune haemolytic anaemia is a rare disorder characterized by decompensated acquired haemolysis caused by the host's immune system acting against its own red cell antigens.Concomitant presentation with reticulocytopenia is very rare and a sign of great severity and poor outcome.Treatment options in refractory cases still greatly rely on individual experience and expert opinion. © EFIM 2020.

Entities:  

Keywords:  Haemolytic anaemia; azathioprine; reticulocytopenia

Year:  2020        PMID: 33457372      PMCID: PMC7806294          DOI: 10.12890/2020_002112

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  12 in total

Review 1.  Autoimmune hemolytic anemia.

Authors:  C P Engelfriet; M A Overbeeke; A E von dem Borne
Journal:  Semin Hematol       Date:  1992-01       Impact factor: 3.851

2.  Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.

Authors:  Bruno Fattizzo; Anna Zaninoni; Francesco Nesa; Veronica M Sciumbata; Alberto Zanella; Agostino Cortelezzi; Wilma Barcellini
Journal:  Am J Hematol       Date:  2015-08       Impact factor: 10.047

3.  The diagnosis and management of primary autoimmune haemolytic anaemia.

Authors:  Quentin A Hill; Robert Stamps; Edwin Massey; John D Grainger; Drew Provan; Anita Hill
Journal:  Br J Haematol       Date:  2016-12-22       Impact factor: 6.998

4.  Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia.

Authors:  S M Worlledge; M C Brain; A C Cooper; J R Hobbs; J V Dacie
Journal:  Proc R Soc Med       Date:  1968-12-12

5.  Azathioprine.

Authors:  E C Huskisson
Journal:  Clin Rheum Dis       Date:  1984-08

6.  Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases.

Authors:  J L Liesveld; J M Rowe; M A Lichtman
Journal:  Blood       Date:  1987-03       Impact factor: 22.113

Review 7.  Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

Authors:  Charles L Bennett; Samuel M Silver; Benjamin Djulbegovic; Athena T Samaras; C Anthony Blau; Kara J Gleason; Sara E Barnato; Kathleen M Elverman; D Mark Courtney; June M McKoy; Beatrice J Edwards; Cara C Tigue; Dennis W Raisch; Paul R Yarnold; David A Dorr; Timothy M Kuzel; Martin S Tallman; Steven M Trifilio; Dennis P West; Stephen Y Lai; Michael Henke
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

8.  Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency.

Authors:  C L Conley; S M Lippman; P Ness
Journal:  JAMA       Date:  1980-10-10       Impact factor: 56.272

9.  Erythropoietin May Improve Anemia in Patients with Autoimmune Hemolytic Anemia Associated with Reticulocytopenia.

Authors:  Olga Arbach; Robert Funck; Frank Seibt; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2012-05-15       Impact factor: 3.747

Review 10.  Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia.

Authors:  W Barcellini; B Fattizzo
Journal:  Dis Markers       Date:  2015-12-27       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.